ArticleSynthetic and systems biotechnology2025
Efficient production of astaxanthin in
Article in Synthetic and systems biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Systematic enzyme and cofactor engineering for efficient ursolic acid biosynthesis inSynthetic and systems biotechnology · 2027Article
- High-level amyrin production inSynthetic and systems biotechnology · 2027Article
- EngineeringSynthetic and systems biotechnology · 2026Article
- Modular reconstruction and multilevel regulation ofSynthetic and systems biotechnology · 2026Article
- Advances in semi-rational design of terpene synthases and their modifying enzymes.AMB Express · 2025Review
- Beyond pigments and perfumes: engineering in the carotenoid and apocarotenoid spectrum, novel enzymes, and synthetic biology strategies.Frontiers in bioengineering and biotechnology · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astaxanthin is a natural red carotenoid, commonly used as an additive in the pharmaceutical industry and as a nutritional supplement owing to its notable antioxidant benefits. However, a complex biosynthetic pathway poses a challenge to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.